ReviewCurrent hypertension reports2017
Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?
Review in Current hypertension reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Use of Anticoagulants as a Supportive Measure in Pulmonary Hypertension: A Narrative Review.Tuberculosis and respiratory diseases · 2026Article
- Sotatercept for the Treatment of Myeloproliferative Neoplasm-Associated Group 5 Pulmonary Hypertension.JACC. CardioOncology · 2026Article
- Prevalence, Clinical Features, and Treatment Response of Chronic Thromboembolic Pulmonary Hypertension in Patients With Myeloproliferative Neoplasm.Circulation reports · 2026Article
- What can we learn from pathophysiology and therapeutic targetable pathways from all genetic causes and associations in PH?International journal of cardiology. Congenital heart disease · 2024Review
- Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies.Frontiers in oncology · 2023Review
- Sustained response to targeted therapies in a patient with pulmonary hypertension owing to Langerhans cell histiocytosis.Anatolian journal of cardiology · 2021Article
- Article
- Article
- Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report.Annals of the American Thoracic Society · 2019Article
- Approach to a patient with pulmonary hypertension.Journal of geriatric cardiology : JGC · 2019Review
- Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights.International journal of medical sciences · 2019Review
- Pulmonary hypertension associated with neurofibromatosis type 1.European respiratory review : an official journal of the European Respiratory Society · 2018Review
- Possible interesting link between Janus kinase 2 mutation and renovascular hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purpose of this review was to outline the mechanisms and to review recent literature on pulmonary arterial hypertension (PAH) medications in group 5 pulmonary hypertension (PH). RECENT
findingsThe first steps in management are to understand the mechanisms and hemodynamic profile and to exclude chronic thromboembolic disease. Recent studies in the past 5 years have found that PAH medications may improve hemodynamics in patients with pre-capillary pulmonary hypertension due to sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis, and myeloproliferative disorders with dasatinib-induced PH. Improvements in exercise capacity are uncommon, and no survival benefit has been demonstrated. There is a risk of pulmonary edema in patients with pulmonary venous involvement or fibrosing mediastinitis when treated with PAH therapies. There is limited evidence supporting the use of PAH medications in group 5 patients, and they may be harmful in certain cases. In most patients with group 5 PH, treatment should be directed to the underlying disease with PAH therapies reserved for patients with severe pre-capillary PH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.